Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

Meropenem

To administer 2g daily 8 hourly for 14 days

DRUG

Faropenem

To adminster 600mg 8 hourly daily for 14 days

DRUG

Amoxycillin/clavulanic acid

To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem

DRUG

Rifafour e275

To be taken as per the National TB treatment programme for 14 days

Trial Locations (1)

7530

TASK Foundation NPC, Cape Town

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eduardo Mondlane University

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Barcelona Centre for International Health Research

OTHER

collaborator

Research Center Borstel

OTHER

lead

TASK Applied Science

OTHER

NCT02349841 - Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis | Biotech Hunter | Biotech Hunter